已收盤 02-06 16:00:00 美东时间
+0.620
+1.82%
今日重点评级关注:HC Wainwright & Co.:维持奥麦罗制药"买入"评级,目标价从20美元升至40美元;HC Wainwright & Co.:维持Cullinan Therapeutics"买入"评级,目标价从26美元升至27美元
01-09 20:22
TD Cowen analyst Hoang Nguyen maintains PROG Holdings (NYSE:PRG) with a Buy and lowers the price target from $41 to $38.
01-09 02:09
今日重点评级关注:富国银行:维持Milestone Pharmaceuticals"超配"评级,目标价从4美元升至8美元;富国银行:维持Kyverna Therapeutics"超配"评级,目标价从31美元升至33美元
2025-12-17 10:46
B. Riley Securities analyst Hal Goetsch initiates coverage on PROG Holdings (NYSE:PRG) with a Buy rating and announces Price Target of $50.
2025-12-16 23:06
Expands PROG Holdings' growing ecosystem through a new, scalable customer acquisition channel that complements its existing payment solutionsCreates access to an employee-focused consumer base with limited overlap across
2025-12-02 06:13
BTIG analyst Vincent Caintic upgrades PROG Holdings (NYSE:PRG) from Sell to Neutral.
2025-11-21 19:06
今日重点评级关注:摩根士丹利:维持Viking Therapeutics"超配"评级,目标价从98美元升至102美元;摩根大通:维持IDEAYA Biosciences"超配"评级,目标价从74美元升至79美元
2025-10-24 09:51
BTIG analyst Vincent Caintic maintains PROG Holdings (NYSE:PRG) with a Sell and raises the price target from $27 to $31.
2025-10-23 18:06
PROG Holdings (NYSE:PRG) raises FY2025 Adj EPS guidance from $3.20-$3.35 to $3.35-$3.45 vs $3.33 analyst estimate. Lowers FY2025 sales outlook from $2.450 billion-$2.500 billion to $2.410 billion-$2.435 billion vs $2.474
2025-10-22 19:37
PROG Holdings (NYSE:PRG) reported quarterly earnings of $0.90 per share which beat the analyst consensus estimate of $0.74 by 21.62 percent. This is a 16.88 percent increase over earnings of $0.77 per share from the same
2025-10-22 19:32